The Low DoseThe GLP-1 price desk
Briefing

Ivím Health vs Ro

$199/mo against $448/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. Ivím Health costs $199 a month and Ro costs $448, a difference of $249 a month or about $2,988 a year. The desk reads it as follows.

Ivím Health is unlimited clinician access. Ro is branded medication with insurance help. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. Ivím Health advertises $199 and bills $199; Ro advertises $149 and bills $448. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

IvímRo
Advertised$199$149
Billed$199$448
Gapnone+$299
Per year, billed$2,388$5,376

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

2 differences on the record. The others match.

IvímRo
Will pursue insurance coverageNoYes
Can dispense FDA-approved branded medicationNoYes

What each puts on the record: Ivím Health

  • Includes holistic coaching, wellness masterclasses and a tracking app.
  • New patients are offered a complimentary 30-minute consultation.

Where it wins: Unlimited clinician visits at a flat rate — unusual at this price. Watch for: Pharmacy sourcing is not published. Ask which pharmacy fills your prescription and whether it is 503A or 503B before starting.

What each puts on the record: Ro

  • Effective all-in cost commonly lands between $298 and $598/month depending on the medication and any insurance coverage.
  • Cancellation requires notice before the renewal date.

Where it wins: FDA-approved medication only, which removes the compounding-regulation question entirely. Watch for: The membership and the medication are two separate bills. A $39 first month does not mean a $39 prescription.

In each one’s favour

Ivím Health.

  • Unlimited clinician visits at a flat rate — unusual at this price.
  • Weekly dose review rather than a fixed monthly escalation.

Ro.

  • FDA-approved medication only, which removes the compounding-regulation question entirely.
  • Genuine help pursuing insurance coverage.

Ivím Health scores higher overall at 4 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

The desk’s call

The board says Ivím Health. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

The verdict

On the board, Ivím Health at $199 a month is the more defensible choice on arithmetic alone. Ro earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: Ivím Health and Ro.

How they sit against everyone else

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none—
Ozari Health$125$125none—
Fifty 410$133$133none+$8/mo

More from the desk

  • Ivím Health tirzepatide review

    Advertised at $199 and billed at $199 — no gap. Position 6 of 18 on our board.

  • Ro tirzepatide review

    Advertised at $149, billed at $448. Position 17 of 18 on our board.

  • How to spot a bad seller

    The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

  • The twelve-month cost

    Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure